Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
about
Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET ImagingImaging radiation response in tumor and normal tissue.Imaging tumor hypoxia to advance radiation oncologyPositron emission tomography to assess hypoxia and perfusion in lung cancerAcoustic angiography: a new imaging modality for assessing microvasculature architectureTreatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenationImaging hypoxia in orthotopic rat liver tumors with iodine 124-labeled iodoazomycin galactopyranoside PET.Molecular mechanisms of hypoxia in cancer.Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy.PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidenceCoordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseThe radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptakeHypoxia imaging using PET and SPECT: the effects of anesthetic and carrier gas on [Cu]-ATSM, [Tc]-HL91 and [F]-FMISO tumor hypoxia accumulation.Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Imaging hypoxia in gliomas.PET of hypoxia and perfusion with 62Cu-ATSM and 62Cu-PTSM using a 62Zn/62Cu generator.Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment.Molecular imaging in cancer treatment.Gaussian mixture model-based classification of dynamic contrast enhanced MRI data for identifying diverse tumor microenvironments: preliminary resultsEvaluation of hypoxia in a feline model of head and neck cancer using ⁶⁴Cu-ATSM positron emission tomography/computed tomography.Positron emission tomography imaging of cancer biology: current status and future prospectsImaging and cancer: a review.Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.Applications of molecular imaging.Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model.Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis.Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in MiceCopper-64 Radiopharmaceuticals for Oncologic ImagingStrategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.Accuracy and reproducibility of tumor positioning during prolonged and multi-modality animal imaging studies.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.On the impact of functional imaging accuracy on selective boosting IMRTPET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.Molecular imaging of hypoxia with radiolabelled agents
P2860
Q26784016-7869E92E-073E-4391-8BD7-F0216835193BQ26798266-5D879F41-D59C-4D17-94AF-F643A85D7E79Q27007862-B8AD80E3-4439-474A-ABC5-F890789DCB7AQ27026940-4554E5E5-22D6-4530-8AEE-FFAEC84EBD58Q30449927-F757347C-2EB6-4415-8730-28705B2C5A1EQ33258552-E2F17D78-9452-4013-8EDE-344AEC501208Q33555278-9CF8E851-5464-408B-A389-EC43DDFA014FQ33705108-F3615CA6-F4FA-4DC8-898C-669BAF17E580Q33790254-6CEA140E-CCCF-4920-9F37-9F65CD39F5D2Q33818999-67ACEE8E-5D52-4DC9-BC38-E674374565BEQ33870879-1932139E-A99D-4B07-9C78-FA04B89155F4Q33949625-E4FF5BA3-A58E-4351-B86A-C922A3383239Q34079208-42BBCDAB-95E3-4133-ADC3-263A1E924B98Q34119201-7E9CE5EA-8892-445D-AD99-1F404290FAB7Q34203937-6A2CD174-2A49-4DE2-BAB9-C894E852AE02Q34305022-8C198CCC-BCC2-4BAC-AA9F-BB5D565F71ACQ34315607-1D9D08FC-F3CA-4A90-9ECA-AB36B85A74E2Q34377146-D2F15D28-6183-4251-99BC-391462EE7B5EQ34496670-C2896824-A270-4C45-990C-05D1EDB9B081Q34601310-70FFAF53-0565-456B-B4B8-CFE37760FFFAQ34696310-AB1C5CF9-3E24-453E-A7FA-5FC6F0C23CBCQ34697688-F81590CD-B2B5-444B-BCD5-5281C0755BA7Q34977050-4D781F39-639B-43C3-A3F7-942DB88C07D0Q35029884-C94DB8A9-BB31-4163-97FF-FACB2DCECF40Q35082412-37C7927F-D7DC-4ABF-9CFE-1579689CBCF1Q35172917-9D9E3FC2-9A71-455F-B8F4-7F6A79EC6F2BQ35198160-91739926-BAAA-4CD9-A7E8-8B88D1FEFB6DQ35670487-65FC9B82-E7AF-4015-82CB-F5C5D4D5A8FEQ35769008-755F1C27-CF9B-4A02-82FF-8878B335BEB3Q35821298-0492B47C-8C18-41EA-9323-98A324E79E0DQ36335266-370384E3-CC45-44F1-A5A9-EFC0A9E01E4EQ37126530-2DBCF3D3-F625-4526-A714-E2897B32ADC6Q37137456-43B3AC1B-98E8-4432-A2F3-5DE60E84037CQ37140996-D64DEE7B-2384-4B86-A815-8693904E7167Q37158006-4ECA28B9-7A8B-46E0-84ED-F51D162DAD10Q37236103-DC2C2A0A-FB76-4BAE-89E0-B4577D77385CQ37297515-1A0D3375-E0AC-4C6C-B732-D2094A140F3DQ37332199-612E1904-F55E-4B58-A7B4-1C270BF2D705Q37374442-6787A197-9C6E-4D22-98BB-3345F8AB44D2Q37378239-AF9B2AB6-B24A-4D36-8433-F7882D87C852
P2860
Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@ast
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@en
type
label
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@ast
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@en
prefLabel
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@ast
Intertumoral differences in hy ...... s(N4-methylthiosemicarbazone).
@en
P2093
P1476
Intertumoral differences in hy ...... is(N4-methylthiosemicarbazone)
@en
P2093
James E Bowsher
Laurence W Hedlund
Mark W Dewhirst
Terence Wong
Thies Schroeder
P304
P407
P577
2006-06-01T00:00:00Z